Retrovirus-mediated in Vivo Gene Therapy Using the Herpes Simplex Virus Thymidine Kinase Gene against Carcinomatous Peritonitis

References

• Wright TL, Venook AP, Millward-Sadler GH. Hepatic tumors. In: Millward-Sadler GH, Wright R, Arthur MJP, editors. Wright’s liver and biliary disease. 3rd ed. London: WB Saunders; 1992. p. 1079–121.
   Google Scholar
• Hatori N. Epidemiology of liver cancer in Japan. J Clin Exp Med 1994;171:1097–104.
   Google Scholar
• Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science 1995;270:404–10.
   PubMed Web of Science ®Google Scholar
• Marcel T, Grausz JD. The TMC worldwide gene therapy enrollment report (June 1996). Hum Gene Ther 1996;7:2025–46.
   PubMedGoogle Scholar
• Kuriyama S, Yoshikawa M, Ishizaka S, Tsujii T, Ikenaka K, Kagawa T, et al. A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector. Cell Struct Funct 1991;16:503–10.
   PubMed Web of Science ®Google Scholar
• Kuriyama S, Sakamoto T, Masui K, Nakatani T, Tominaga K, Kikukawa M, et al. Tissue-specific expression of HSV-tk gene can induce efficient antitumor effect and protective immunity to wild-type hepatocellular carcinoma. Int J Cancer 1997;71: 470–5.
   PubMedGoogle Scholar
• Cao G, Kuriyama S, Du P, Sakamoto T, Yang W, Masui K, et al. Construction of retroviral vectors to induce strong hepatoma cell-specific expression of cytokine genes. J Gastroenterol Hepatol 1996;11:1053–61.
   PubMedGoogle Scholar
• Cao G, Kuriyama S, Du P, Sakamoto T, Kong X, Masui K, et al. Complete regression of established murine hepatocellular carcinoma by in vivo tumor necrosis factor a gene transfer. Gastroenterology 1997;112:501–10.
   PubMed Web of Science ®Google Scholar
• Kuriyama S, Nakatani T, Masui K, Sakamoto T, Tominaga K, Yoshikawa M, et al. Bystander effect caused by suicide gene expression indicates the feasibility of gene therapy for hepatocellular carcinoma. Hepatology 1995;22:1838–46.
   PubMedGoogle Scholar
• Kuriyama S, Kikukawa M, Masui K, Okuda H, Nakatani T, Akahane T, et al. Cancer gene therapy with HSV-tk/GCV system depends on T-cell-mediated immune responses and causes apoptotic death of tumor cells in vivo. Int J Cancer 1999;83:374–80.
   PubMed Web of Science ®Google Scholar
• Kuriyama S, Mitoro A, Yamazaki M, Tsujinoue H, Nakatani T, Akahane T, et al. Comparison of gene therapy with the herpes simplex virus thymidine kinase gene and the bacterial cytosine deaminase gene for the treatment of hepatocellular carcinoma. Scand J Gastroenterol 1999;34:1033–41.
   PubMed Web of Science ®Google Scholar
• Kuriyama S, Masui K, Kikukawa M, Sakamoto T, Nakatani T, Nagao S, et al. Complete cure of established murine hepatocellular carcinoma is achievable by repeated injections of retroviruses carrying the herpes simplex virus thymidine kinase gene. Gene Ther 1999;6:525–33.
   PubMedGoogle Scholar
• Yang L, Hwang R, Pandit L, Gordon EM, Anderson WF, Parekh D. Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir. Ann Surg 1996;224:405–17.
   PubMed Web of Science ®Google Scholar
• Aoki K, Yoshida T, Matsumoto N, Ide H, Hosokawa K, Sugimura T, et al. Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene. Hum Gene Ther 1997; 8:1105–13.
   PubMed Web of Science ®Google Scholar
• Coll J-L, Mesnil M, Lefebvre M-F, Lancon A, Favrot MC. Long-term survival of immunocompetent rats with intraperitoneal colon carcinoma tumors using herpes simplex thymidine kinase/ganciclovir and IL-2 treatments. Gene Ther 1997;4: 1160–6.
   Google Scholar
• Lechanteur C, Princen F, Lo Bue S, Detroz B, Fillet G, Gielen J, et al. HSV-1 thymidine kinase gene therapy for colorectal adenocarcinoma-derived peritoneal carcinomatosis. Gene Ther 1997;4:1189–94.
   PubMed Web of Science ®Google Scholar
• Princen F, Lechanteur C, Lopez M, Rocoux G, Detroz B, Gielen J, et al. Repeated cycles of retrovirus-mediated HSVtk gene transfer plus ganciclovir increase survival of rats with peritoneal carcinomatosis. Gene Ther 1998;5:1054–60.
   PubMed Web of Science ®Google Scholar
• Sato H, Belkin M, Essner E. Experiments on an ascites hepatoma. III. The conversion of mouse hepatoma into the ascitic form. J Natl Cancer Inst 1956;17:1–21.
   Google Scholar
• Kuriyama S, Yoshikawa M, Tominaga K, Nakatani T, Sakamoto T, Fukui H, et al. Gene therapy for the treatment of hepatoma by retroviral-mediated gene transfer of the herpes simplex virus thymidine kinase. Int Hepatol Commun 1993;1:253–9.
   Google Scholar
• Cao G, Kuriyama S, Gao J, Mitoro A, Cui L, Nagao S, et al. In vivo gene transfer of a suicide gene under the transcriptional control of the carcinoembryonic antigen promoter results in bone marrow transduction but can avoid bone marrow suppression. Int J Oncol 1999;15:107–12.
   PubMedGoogle Scholar
• Smythe WR, Hwang HC, Elshami A, Amin KM, Eck SL, Davidson BL, et al. Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann Surg 1995;222:78–86.
   PubMed Web of Science ®Google Scholar
• Lan K-H, Kanai F, Shiratori Y, Ohashi M, Tanaka T, Okudaira T, et al. In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma. Cancer Res 1997;57: 4279–84.
   Google Scholar
• Gao G, Kuriyama S, Gao J, Kikukawa M, Cui L, Nakatani T, et al. Effective and safe gene therapy for colorectal carcinoma using the cytosine deaminase gene directed by the carcinoem-bryonic antigen promoter. Gene Ther 1999;6:83–90.
   PubMedGoogle Scholar
• Cao G, Kuriyama S, Cui L, Nagao S, Pan X, Toyokawa Y, et al. Analysis of the human carcinoembryonic antigen promoter core region in colorectal carcinoma-selective cytosine deaminase gene therapy. Cancer Gene Ther 1999;6:572–80.
   PubMedGoogle Scholar
• Patijn GA, Lieber A, Meuse L, Winther B, Kay MA. Highefficiency retrovirus-mediated gene transfer into the livers of mice. Hum Gene Ther 1998;9:1449–56.
   PubMedGoogle Scholar
• Elshami AA, Saavedra A, Zhang H, Kucharczuk JC, Spray DC, Fishman GI, et al. Gap junctions play a role in the ‘bystander effect’ of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther 1996;3:85–92.
   PubMed Web of Science ®Google Scholar
• Kianmanesh AR, Perrin H, Panis Y, Fabre M, Nagy HJ, Houssin D, et al. A ‘distant’ bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor. Hum Gene Ther 1997;8:1807–14.
   PubMed Web of Science ®Google Scholar
• Vile RG, Castleden S, Marshall J, Camplejohn R, Upton C, Chong H. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer 1997;71:267–74.
   PubMed Web of Science ®Google Scholar
• Colombo BM, Benedetti S, Ottolenghi S, Mora M, Pollo B, Poli G, et al. The ‘bystander effect’: association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum Gene Ther 1995;6:763–72.
   PubMed Web of Science ®Google Scholar
• Gagandeep S, Brew R, Green B, Christmas SE, Klatzmann D, Poston GJ, et al. Prodrug-activated gene therapy: involvement of an immunological component in the ‘bystander effect.’ Cancer Gene Ther 1996;3:83–8.
   PubMed Web of Science ®Google Scholar
• Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;60:397–403.
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Biology of natural killer cells. Adv Immunol 1989;47:187–376.
   PubMed Web of Science ®Google Scholar
• Smith KA. Interleukin 2: inception, impact, and implications. Science 1988;240:1169–76.
   PubMed Web of Science ®Google Scholar
• Parkinson DR. Interleukin 2 in cancer therapy. Semin Oncol 1988;15:10–26.
   PubMed Web of Science ®Google Scholar
• Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991;9:694–704.
   PubMed Web of Science ®Google Scholar